3Minna JD,Pass H,Glatstein E,et al.Cancer of the lung [M].In: DeVita V,Hellman S,Rosenberg SA(ed).Cancer Principles and Practice of Oncology.Philadelphia:Lippincott,1989:591- 705.
4Souquet PJ,Chauvin F,Boissel JP,et al.Polychemotherapy in advanced non small cell lung cancer:A meta analysis [J].Lancet,1993,342:19- 21.
5Marino P,Pampallona S,Preatoni A,et al.Chemotherapy vs supportive care in advanced non small cell lung cancer.Results of a meta analysis of the literature [J].Chest,1994,106:861- 865.
6Bonomi PD,Finkelstein PM,Ruckdeschel JC,et al.Combination chemotherapy versus single agents followed by combination chemotheapy in stage Ⅳ non small cell lung cancer:a study of the Eastern Cooperative Oncology Group [J].J Clin Oncol,1989,7:1602- 1613.
7Preti P,Poggi G,Cuomo AM,et al.Phase II study with ifosfamide,carboplatin,etoposide (ICE regimen) at intermediate dosage for advanced non small cell lung cancer (NSCLC) [J].J Chemother,1998 ,10(6):492- 495.
8Hsieh RK,Chang AY,Boros L,et al.Phase II study of ifosfamide,carboplatin,and etoposide in patients with advanced non- small cell lung cancer [J].Am J Clin Oncol,1994 ,17(6):509- 513.
9Kosmidis P,Mylonakis N,Skarlos D,et al.Paclitaxel (175 mg/m2) plus carboplatin (6 AUC) versus paclitaxel (225 mg/m2) plus carboplatin (6 AUC) in advanced non small cell lung cancer (NSCLC): a multicenter randomized trial.Hellenic Cooperative Oncology Group(HeCOG) [J].Ann Oncol,2000 ,11(7):799- 805.
10Kearns CM,Belani CL,Erkmen K,et al.Reduced platelet toxicity with combination carboplatin and paclitaxel:Pharmacodynamic modulation of carboplatin- associated thromboctopenia (absstract) [C].Proc Am Soc Clin Oncol,1995,14:170.
